Document is current
Any future updates will be listed below
-
Authors
Tapiainen, Vilja V.
Sirniö, Päivi
Elomaa, Hanna
Karjalainen, Henna
Äijälä, Ville K.
Kastinen, Meeri
Kehusmaa, Akseli
Pohjanen, Vesa-Matti
Lindgren, Outi
Sirkiä, Onni
Ahtiainen, Maarit
Helminen, Olli
Wirta, Erkki-Ville
Rintala, Jukka
Saarnio, Juha
Rautio, Tero
Seppälä, Toni T.
Böhm, Jan
Mecklin, Jukka-Pekka
Tuomisto, Anne https://orcid.org/0000-0002-9949-1887
Mäkinen, Markus J. https://orcid.org/0000-0002-9200-4118
Väyrynen, Juha P. https://orcid.org/0000-0002-8683-2996
-
Funding
Funding for this research was provided by:
Emil Aaltosen Säätiö (220257P)
Sigrid Juséliuksen Säätiö (230229)
Syöpäsäätiö (69-7354)
Finnish State Research Funding
- License Information
-
More Information
Article History
Received: 7 October 2024
Revised: 5 February 2025
Accepted: 25 February 2025
First Online: 7 March 2025
Competing interests
: TTS reports consultation fees from Tillots Pharma, Mehiläinen and Nouscom, being a co-owner and CEO of Healthfund Finland Ltd, and a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. The other authors declare that they have no conflicts of interest.
: The study was conducted in accordance with the Declaration of Helsinki. For Cohort 1, the study was conducted under approval from the Regional medical research ethics committee of the Wellbeing services county of Central Finland (Dnro 13U/2011, 1/2016, 8/2020, 2/2023), Central Finland Biobank (BB23-0172), and Fimea (Dnro FIMEA/2023/001573, 4/2023). For Cohort 2, the study was conducted under approval from the Regional medical research ethics committee of the Wellbeing services county of North Ostrobothnia (25/2002, 42/2005, 122/2009, 37/2020), Biobank Borealis (BB-2017_1012) and Fimea (FIMEA/2022/001941). In Cohort 2, all participants gave written informed consent for the study. For Cohort 1, The need to obtain informed consent from the study patients was waived (Dnro FIMEA/2023/001573, 4/2023).
